We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » New Recommendations Pinpoint Who Starts Aduhelm Treatment and When to Stop
New Recommendations Pinpoint Who Starts Aduhelm Treatment and When to Stop
Patients who want to start treatment with Biogen’s newly approved Alzheimer’s drug, Aduhelm (aducanumab), should undergo cognitive testing, brain imaging to exclude cerebrovascular disease and have either a lumbar puncture or PET scan to confirm the presence of cerebral amyloid, a new set of treatment recommendations advises.